WASHINGTON--(BUSINESS WIRE)--The changes proposed by the Securities and Exchange Commission (SEC) and the Public Companies Accounting Oversight Board (PCAOB) to modify the Sarbanes-Oxley Act of 2002 (SOX) provide a “marginal improvement” for emerging biotechnology companies, BIO President and CEO Jim Greenwood told a congressional committee today. Greenwood made his comments as he testified before the House of Representatives’ Small Business Committee on how the new rules governing implementation of SOX will affect the biotechnology industry.
